Astria Therapeutics, Inc. (ATXS) - Dilution Analysis

POS AM filing: This post-effective amendment relates to multiple registration statements on Form S-3 and declares the termination of the offering and sale of securities under these registration statements due to a merger with BioCryst Pharmaceuticals, Inc.

POS AM filing: This is a post-effective amendment to deregister securities from six registration statements (333-212382, 333-231441, 333-254174, 333-264911, 333-271848, and 333-276057) due to the merger of Astria Therapeutics, Inc. with a subsidiary of BioCryst Pharmaceuticals, Inc., which terminated the offering and sale of securities under these registration statements.

POS AM filing: This filing relates to the deregistration of securities previously registered under multiple Form S-3 registration statements due to the merger of Astria Therapeutics, Inc. with a subsidiary of BioCryst Pharmaceuticals, Inc., which terminated the offering and sale of these securities.

10-Q filing | 58.0M shares outstanding

10-Q filing | 58.0M shares outstanding

10-K filing | 56.2M shares outstanding

10-Q filing | 57.8M shares outstanding

10-Q filing | 56.5M shares outstanding

10-Q filing | 52.3M shares outstanding

10-K filing | 41.0M shares outstanding

8-K filing: Astria Therapeutics, Inc. entered into an underwriting agreement for an underwritten offering of 10,340,000 shares of common stock at a price of $12.09 per share, with the offering expected to close on or about February 1, 2024. ($124.99M proceeds)

8-K filing: Astria Therapeutics, Inc. announced the sale of the remaining $50.0 million of its common stock under its at-the-market offering program with Jefferies LLC, resulting in the issuance and sale of 7,684,412 shares for net proceeds of $48.5 million. As of January 29, 2024, the Company had 43,980,603 shares of Common Stock outstanding. ($48.5M proceeds)

S-3/A filing: Astria Therapeutics files an S-3/A form to offer securities from time to time in one or more offerings up to $500,000,000 in aggregate offering price.

S-3 filing: Astria Therapeutics, Inc. may offer and sell securities from time to time in one or more offerings of up to $500,000,000 in aggregate offering price.

10-Q filing | 28.0M shares outstanding

8-K filing: Astria Therapeutics, Inc. announced an underwritten offering of 8,253,895 shares of common stock and accompanying warrants, and pre-funded warrants to purchase 1,571,093 shares of common stock and accompanying warrants, with an expected closing on or about October 16, 2023, and anticipates net proceeds of approximately $59.6 million. ($64.0M proceeds)

10-Q filing | 28.0M shares outstanding

10-Q filing | 27.9M shares outstanding

S-3 filing: Astria Therapeutics, Inc. files an S-3 registration statement for the potential offering of up to $250,000,000 in aggregate offering price of various securities including common stock, preferred stock, depositary shares, units and warrants.

10-K filing | 27.5M shares outstanding

8-K filing: Astria Therapeutics, Inc. entered into an underwriting agreement for an offering of 9,082,653 shares of common stock at $11.01 per share, with an option for the underwriters to purchase an additional 1,362,397 shares, expecting net proceeds of approximately $93.6 million. ($100.0M proceeds)

10-Q filing | 16.8M shares outstanding

8-K filing: Astria Therapeutics increased the amount of its common stock that may be offered under the At-the-Market Offering Program to an aggregate offering price of up to $88,135,305.48. As of November 9, 2022, there were 17,051,429 shares of the Company's common stock outstanding. ($38.14M proceeds)

8-K filing: Astria Therapeutics increased the amount of common stock that may be offered under its at-the-market offering program to an aggregate offering price of up to $50,000,000. As of September 15, 2022, there were 15,178,042 shares of the Company's common stock outstanding. ($19.5M proceeds)

10-Q filing | 13.0M shares outstanding

S-3 filing: Astria Therapeutics files an S-3 shelf registration to offer and sell up to $250,000,000 of common stock, preferred stock, depositary shares, units, and warrants from time to time in one or more offerings.

10-Q filing | 13.0M shares outstanding

10-K filing | 13.0M shares outstanding

10-Q filing | 12.8M shares outstanding

8-K filing: Stock split one-for-six | Outstanding: 76,948,803 → 12,824,800

10-Q filing | 76.9M shares outstanding

10-Q filing | 23.4M shares outstanding

S-3/A filing: This S-3/A filing relates to the proposed resale or other disposition of 92,399,805 shares of common stock by selling stockholders.

S-3 filing: This S-3 filing pertains to the proposed resale of 92,399,805 shares of common stock by selling stockholders, consisting of shares issued in connection with the acquisition of Quellis Biosciences, Inc. and shares issuable upon the conversion of Series X Convertible Preferred Stock.

8-K filing: Catabasis Pharmaceuticals acquired Quellis Biosciences through a merger, issuing 3,332,669 shares of common stock and 50,504 shares of newly designated Series X Preferred Stock to Quellis stockholders, and also entered into a Stock Purchase Agreement to sell approximately 35,573 shares of Series X Preferred Stock for $110.0 million. ($110.0M proceeds)

10-Q filing | 20.1M shares outstanding

10-Q filing | 19.1M shares outstanding

10-Q filing | 17.9M shares outstanding

10-K filing | 17.9M shares outstanding